首页> 美国卫生研究院文献>Journal of Virology >The Imidazopyrrolopyridine Analogue AG110 Is a Novel Highly Selective Inhibitor of Pestiviruses That Targets the Viral RNA-Dependent RNA Polymerase at a Hot Spot for Inhibition of Viral Replication
【2h】

The Imidazopyrrolopyridine Analogue AG110 Is a Novel Highly Selective Inhibitor of Pestiviruses That Targets the Viral RNA-Dependent RNA Polymerase at a Hot Spot for Inhibition of Viral Replication

机译:咪唑并吡咯并吡啶类似物AG110是瘟病毒的新型高选择性抑制剂可将热点RNA依赖的RNA聚合酶靶向于抑制病毒复制的热点

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Ethyl 2-methylimidazo[1,2-a]pyrrolo[2,3-c]pyridin-8-carboxylate (AG110) was identified as a potent inhibitor of pestivirus replication. The 50% effective concentration values for inhibition of bovine viral diarrhea virus (BVDV)-induced cytopathic effect, viral RNA synthesis, and production of infectious virus were 1.2 ± 0.5 μM, 5 ± 1 μM, and 2.3 ± 0.3 μM, respectively. AG110 proved inactive against the hepatitis C virus and a flavivirus. AG110 inhibits BVDV replication at a time point that coincides with the onset of intracellular viral RNA synthesis. Drug-resistant mutants carry the E291G mutation in the viral RNA-dependent RNA polymerase (RdRp). AG110-resistant virus is cross-resistant to the cyclic urea compound 1453 which also selects for the E291G drug resistance mutation. Moreover, BVDV that carries the F224S mutation (because of resistance to the imidazopyridine 5-[(4-bromophenyl)methyl]-2-phenyl-5H-imidazo[4,5-c]pyridine [BPIP]and VP32947) is also resistant to AG110. AG110 did not inhibit the in vitro activity of recombinant BVDV RdRp but inhibited the activity of BVDV replication complexes (RCs). Molecular modeling revealed that E291 is located in a small cavity near the tip of the finger domain of the RdRp about 7 Å away from F224. Docking of AG110 in the crystal structure of the BVDV RdRp revealed several potential contacts including with Y257. The E291G mutation might enable the free rotation of Y257, which might in turn destabilize the backbone of the loop formed by residues 223 to 226, rendering more mobility to F224 and, hence, reducing the affinity for BPIP and VP32947. It is concluded that a single drug-binding pocket exists within the finger domain region of the BVDV RdRp that consists of two separate but potentially overlapping binding sites rather than two distinct drug-binding pockets.
机译:2-甲基咪唑并[1,2-a]吡咯并[2,3-c]吡啶-8-羧酸酯(AG110)被鉴定为瘟病毒复制的有效抑制剂。抑制牛病毒性腹泻病毒(BVDV)引起的细胞病变效应,病毒RNA合成和感染性病毒产生的50%有效浓度值分别为1.2±0.5μM,5±1μM和2.3±0.3μM。 AG110被证明对丙型肝炎病毒和黄病毒无活性。 AG110在与细胞内病毒RNA合成开始的时间点抑制BVDV复制。耐药突变体在病毒RNA依赖性RNA聚合酶(RdRp)中携带E291G突变。耐AG110的病毒对环状脲化合物1453具有交叉耐药性,该化合物也选择E291G耐药性突变。此外,带有F224S突变的BVDV(由于对咪唑并吡啶5-[(4-溴苯基)甲基] -2-苯基-5H-咪唑并[4,5-c]吡啶[BPIP]和VP32947的抵抗力)至AG110。 AG110不会抑制重组BVDV RdRp的体外活性,但会抑制BVDV复制复合物(RCs)的活性。分子建模表明,E291位于距离R224约7Å的RdRp指状结构域末端附近的小空腔中。 AG110对接在BVDV RdRp的晶体结构中显示出一些潜在的接触,包括与Y257的接触。 E291G突变可能使Y257能够自由旋转,进而使由残基223至226形成的环的骨架不稳定,从而使F224具有更大的迁移性,从而降低了对BPIP和VP32947的亲和力。结论是,在BVDV RdRp的指域区域内存在一个单一的药物结合袋,该结合袋由两个单独的但可能重叠的结合位点组成,而不是两个不同的药物结合袋。

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号